New paper in nature: large scale screening reveals potential anti coronavirus drugs

category:Global
 New paper in nature: large scale screening reveals potential anti coronavirus drugs


A practical strategy for novel coronavirus pneumonia (COVID-19) therapy is to reuse drugs that have been approved or are in clinical research stage because the pharmacological activity and safety of these drugs have been confirmed.

Sumit Chanda and colleagues at the plybis Institute of medical discovery in Sanford Burnham, California, USA, and colleagues described an assessment of nearly 12, A large-scale screening study of 000 drugs to block the replication potential of the new coronavirus has resulted in the discovery of 100 molecules that can inhibit the replication of the virus, 13 of which show particularly impressive characteristics - especially at realistic dose levels.

(function(){( window.slotbydup=window .slotbydup||[]).push({id:u5811557,container:ssp_ 5811557, async:true }These include: the anti HIV drug r82913; ds-6930, a member of the drug family (PPAR - u03b3 agonists) used to treat diabetes; ono5334, a potential drug for the treatment of osteoporosis; and apimod, an autoimmune disease such as Crohns disease. Studies have shown that the three most effective are ono5334, apimod and mdl28170 (mdl28170 has been shown to attenuate Ebola virus infection). Using cultured lung tissue, the researchers tested the ability of the three drugs to reduce the replication of sars-cov-2. The results showed that ono5334, mdl28170 and apimod reduced the number of infected cells by 72%, 65% and 85%, respectively. It has previously been shown that apimod is well tolerated in humans and is safe in the dose range that may produce antiviral effects. Source: surging news editor: Wang Ning_ NB12468

These drugs include: the anti HIV drug r82913; ds-6930, a member of the drug family (PPAR - u03b3 agonists) used to treat diabetes; ono5334, a potential drug for osteoporosis; and apimod, which treats autoimmune diseases such as Crohns disease.

Studies have shown that the three most effective are ono5334, apimod and mdl28170 (mdl28170 has been shown to attenuate Ebola virus infection). Using cultured lung tissue, the researchers tested the ability of the three drugs to reduce the replication of sars-cov-2. The results showed that ono5334, mdl28170 and apimod reduced the number of infected cells by 72%, 65% and 85%, respectively. It has previously been shown that apimod is well tolerated in humans and is safe in the dose range that may produce antiviral effects.